In 2010, Graeser et al. evaluated RAD51 focus formation in a cohort of 68 breast cancer patients from core biopsy tumor samples at 24 h post- neoadjuvant anthracycline-based chemotherapy [127]. This evidence concerns the gene RAD51 and breast carcinoma.